Embedded Files
Press Release
HYPERION THERAPEUTICS TO PRESENT AT BIOTECH SHOWCASE™ 2024
During the 2024 J.P. Morgan Healthcare Conference week in San Francisco, Jennings Luu, MD/PhD Fellow and Founder/CEO of the biopharmaceutical startup, will showcase the Company’s latest developments in bringing a new class of medications to market for the treatment of leading global causes of blindness, which include age-related macular degeneration (AMD), diabetic retinopathy (DR), retinitis pigmentosa (RP), and glaucoma.
Newport Beach, CA – December 30, 2023 – Hyperion Therapeutics, Inc., today announced that it is presenting at Seed Showcase, part of Biotech Showcase™ 2024. This year, the Company’s founder and chief executive will be presenting their roadmap for a new class of small-molecule medications, known as Stress Resilience-Enhancing Drugs (SREDs), currently in late-stage preclinical development for the treatment of various age-related and inherited retinal diseases. Based on their revolutionary Systems Pharmacology platform that leverages the latest breakthroughs in multi-omics technologies, SREDs are on track for initial market introduction within five years, and ultimately, hold the potential to be utilized as broad-spectrum therapies with clinical indications spanning a wide variety of acute and chronic conditions associated with aging, stress, and/or neurodegeneration.
Today, approximately 420 million people worldwide suffer from debilitating vision loss caused by AMD, DR, RP, or glaucoma; a large majority of these cases (up to 90%) have only minimally effective or no treatment options available. These chronic, progressive retinal diseases arise from a combination of genetic and environmental factors that disrupt cellular and tissue stability. Such disruptions accumulate with repeated exposures to stress over time, leading to progressive visual impairment and, in many cases, legal blindness. Despite decades of research, effective treatments to preserve eyesight have remained elusive for the millions of patients suffering from these debilitating disorders, especially in the vast majority of cases that are in earlier stages of disease progression, wherein lies the greatest opportunity to slow or prevent vision loss.
“SREDs represent a promising strategy for patients and clinicians to combat disease in earlier stages with superior efficacy and fewer side effects, substantially bolstering the arsenal of ophthalmic medications currently limited to anti-angiogenics, corticosteroids, and nonsteroidal anti-inflammatory drugs (NSAIDs),” said Jennings Luu, MD/PhD Doctoral Fellow of Pharmacology at Case Western Reserve University and Founder/CEO of Hyperion Therapeutics, Inc. “Ultimately, we envision SREDs becoming a mainstay therapy and standard of care to alleviate suffering across a broad range of debilitating ailments for which there currently exist no viable therapeutic options... [this] paradigm shift will help usher in a new era for humanity in the clinical practice of medicine, whereby human lifespan and healthspan may both be improved pharmacologically, irrespective of disease etiology.”
Registered attendees can view the Hyperion Therapeutics presentation live during the in-person event:
Date: Tuesday, January 9, 2024
Time: 2:40PM
Track: Franciscan D (Ballroom Level)
“We are excited to be presenting our recent accomplishments and plans for the future at Biotech Showcase 2024, and we look forward to exploring opportunities for strategic alliances with global partners.” – Jennings Luu, Founder and President/CEO
Seed Showcase, as part of Biotech Showcase, is produced by Demy-Colton and EBD Group, and is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters broad geographical investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
“We are delighted that Hyperion Therapeutics will be joining us in San Francisco and presenting at Seed Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Seed Showcase is a prime opportunity for today’s cutting-edge entrepreneurs and motivated investors to come together to discover the potential of technologies that will drive the future of the life science industry.”
ABOUT SEED SHOWCASE
Seed Showcase is part of Biotech Showcase, which is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 16th year, Biotech Showcase is a well-established, highly respected conference featuring multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
ABOUT HYPERION THERAPEUTICS
Hyperion Therapeutics is a seed-stage biopharmaceutical company developing novel, accessible therapies for leading global causes of blindness in degenerative ophthalmic diseases, including Age-related Macular Degeneration, Diabetic Retinopathy, Retinitis Pigmentosa, and Glaucoma. In the pipeline are two medications, SP3 and SP4, entering clinical-phase development with potential FDA-accelerated pathways to market within five years. The third product, SP5, has likewise demonstrated efficacy in genetic or environmental disease models and is now in final stages of preclinical development. The Company is a for-profit, C-Corporation that augments its core scientific and business capabilities through strategic partnerships with academic and industrial entities for optimized capital efficiency. Collaborations with the University of California, Irvine, Center for Translational Vision Research and Beall Applied Innovation enable access to world-renowned scientific advisors, cutting-edge biotechnologies, intellectual property and proprietary research tools that serve as the bedrock of the Company’s drug discovery and development efforts.
Learn more about Hyperion Therapeutics at www.hyperioneye.com.
Follow Hyperion Therapeutics on Twitter at @hyperioneye and Biotech Showcase at @EBDGroup and @Demy_Colton and tag your posts with #BiotechShowcase.
1st Place in the Stella Zhang New Venture Competition!
May 25, 2023 — Awarded First Place Prize in Life Sciences at the 2023 Stella Zhang New Venture Competition, hosted by the Beall Center for Innovation and Entrepreneurship in the Merage School of Business at University of California, Irvine. Congratulations to our incredible team for the award-winning pitch!
1st Place in the Morganthaler-Pavey Startup Competition!
April 11, 2023 — Awarded First Place Prize in the Research Track at the 2023 Morganthaler-Pavey Startup Competition, hosted by the Veale Institute for Entrepreneurship at Case Western Reserve University. Congratulations to Jennings Luu, our Founder/CEO (pictured below), for the award-winning pitch!
Stay tuned for more events coming soon
During the academic year, our affiliates from the Center for Translational Vision Research (CTVR) at the University of California, Irvine (UCI) host a critically acclaimed Distinguished Speaker Seminar Series every Friday, 8:30-10:00am PT, which can be accessed in person at UCI or online via the CTVR website. These weekly seminars showcase groundbreaking discoveries by world-renowned researchers on a broad range of topics, including ophthalmology, pharmacology, genetics, biochemistry, neurobiology, imaging, and computational sciences, while engaging our colleagues from UCI, the region, our nation and beyond. Since its inception, the seminar series has grown internationally in scope, with typical weekly attendance including hundreds of participants from around the world... we invite you all to join in on a lively discussion!
Past events with partners & affiliates
Director of the National Eye Institute, Dr. Michael F. Chiang (top left) speaks during his visit to the UCI CTVR as Distinguished Keynote Speaker. September 16, 2022.
Reception honoring the election of Dr. Kris Palczewski (left) to the National Academy of Sciences, featuring Dr. Philip Kiser and Jennings Luu (right) on guitar. June 15, 2022.
Report abuse